Live
- PM Modi highlights govt's efforts to make Odisha prosperous and one of the fastest-growing states
- Hezbollah fires 200 rockets at northern, central Israel, injuring eight
- Allu Arjun's Family Appearance on Unstoppable with NBK Breaks Viewership Records
- Unity of hearts & minds essential for peace & progress, says J&K Lt Governor
- IPL 2025 Auction: I deserve Rs 18 cr price, says Chahal on being acquired by Punjab Kings
- EAM Jaishankar inaugurates new premises of Indian embassy in Rome
- Sailing vessel INSV Tarini embarks on second leg of expedition to New Zealand
- Over 15,000 people affected by rain-related disasters in Sri Lanka
- IPL 2025 Auction: RCB acquire Hazlewood for Rs 12.50 cr; Gujarat Titans bag Prasidh Krishna at Rs 9.5 crore
- Maharashtra result reflects the outcome of Congress' destructive politics: BJP's Shazia Ilmi
Private equity firm Advent International to acquire majority stake in ZCL Chemicals
Private equity firm Advent International to acquire majority stake in ZCL Chemicals
Private equity fund Advent International on February 8 announced that it has signed a definitive agreement to acquire a majority stake in ZCL Chemicals, formerly known as Zandu Chemicals.
Private equity fund Advent International on February 8 announced that it has signed a definitive agreement to acquire a majority stake in ZCL Chemicals, formerly known as Zandu Chemicals. The transaction represents the third deal in the domestic pharma segment by Advent which has earlier acquired Hyderabad based RA Chem and Bharat Serums and Vaccines.
With this transaction, Morgan Stanley Private Equity Asia, a private equity platform that previously managed a minority investment in ZCL, will exit its investment, the announcement said. The financial terms of the deal were not disclosed.
"ZCL will be our third pharmaceuticals investment in India and the second in the API space. ZCL is a high-growth business, led by a capable management team, which will further fortify our presence in the API market, a key sub-sector focus of ours," said Shweta Jalan, a Managing Director and Head of India at Advent International, India.
"We are impressed with ZCL's differentiated product portfolio, a strong pipeline and its high focus on quality and compliance. The acquisition of ZCL helps us get closer to our goal of creating a top five merchant API platform in India," said Pankaj Patwari, Director, Advent International India.
ZCL operates in the segments of specialty active pharmaceutical ingredients (APIs) and advanced intermediates. It's a highly specialised approach focuses on niche therapeutic areas, underpinned by complex chemistry, supported by a state-of-the-art U.S. Food and Drug Administration (FDA) approved facility, along with strong research & development capabilities.
The firm is developing a strong pipeline of high potential products that are expected to drive the next phase of its growth.
Advent has been investing in India since 2007. In this time, it has deployed over $1.7 billion in 12 companies with headquarters or operations in the country. The PE fund has significant experience in the healthcare industry globally. In the past 30 years, the firm has invested or committed over $9.6 billion in 48 companies in the sector, including over 20 businesses involved in pharmaceutical R&D, production, and distribution.
